Dr. Jastreboff is an Associate Professor at the Yale School of Medicine. She currently serves as the Director of Weight Management and Obesity Prevention, and as the Medical Director of the Yale Stress Center. She is an Obesity Medicine physician-scientist, board certified in adult Endocrinology and Metabolism, Pediatric Endocrinology, and Obesity Medicine.
Dr. Jastreboff is nationally and internationally recognized in the Obesity Medicine field for developing Clinical Practice Guidelines (2016) for The Comprehensive Care of Patients with Obesity (AACE/ACE), serving on the Board of Directors for the American Board of Obesity Medicine (ABOM), educating the next generation of Obesity Medicine physicians by teaching annually at Harvard Blackburn Treating Obesity course and the Columbia/Cornell Obesity course, and conducting cutting-edge clinical translational obesity research.
Her research includes both large, multi-center clinical outcomes trials using anti-obesity medication as well as neuroimaging studies (fMRI and PET) examining the neurobiology underlying obesity and the mechanisms of anti-obesity medications. Recently, Dr. Jastreboff served as the lead author on the SURMOUNT-1 trial investigating novel GIP/GLP-1 receptor agonist, tirzepatide, for the treatment of obesity (Jastreboff, et al., NEJM, 2022).
Dr. Jastreboff received her MD at the University of Maryland School of Medicine and is fellowship-trained in both Endocrinology & Metabolism and Pediatric Endocrinology at Yale University School of Medicine. She completed her PhD at Yale University’s Investigative Medicine Program.